Healthlead PCLBKK:HL -1.79%76 EBITDA Margin % is 8.85% as of Mar. 2026, which is 7% below its 10-year median of 9.47. GuruFocus rates BKK:HL with a GF Score™ of 76/100 and a GF Value™ of ฿10.82 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Healthlead PCL ranks worse than 52.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Healthlead PCL's EBITDA for the
three
months ended in Mar. 2026 was ฿52 Mil. Healthlead PCL's Revenue for the
three
months ended in Mar. 2026 was ฿585 Mil. Therefore, Healthlead PCL's EBITDA margin for the quarter that ended in Mar. 2026 was 8.85%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Healthlead PCL EBITDA Margin % Related Terms
Healthlead PCL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healthlead PCL (BKK:HL) has a EBITDA Margin % of 8.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Healthlead PCL and its competitors. This is near median its historical median of 9.47. Over the past decade, Healthlead PCL's EBITDA Margin % has ranged from 5.00 to 12.28. According to the industry distribution chart, Healthlead PCL ranks #352 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 52.9%.
Is Healthlead PCL's EBITDA Margin % too high?
Healthlead PCL's current EBITDA Margin % of 8.85% is near median its 10-year median of 9.47. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 12.28. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Healthlead PCL's value of 8.85% is 13.6% below this industry median. Based on the distribution chart, Healthlead PCL ranks #352 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #352 out of 665 companies for EBITDA Margin %. This places Healthlead PCL in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Healthlead PCL's value of 8.85% is 13.6% below this benchmark. Historically, Healthlead PCL's own EBITDA Margin % has ranged from 5.00 to 12.28 over the past decade. While the company's 10-year median is 9.47 vs. the industry median of 10.24, Healthlead PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current EBITDA Margin % of 8.85% is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current EBITDA Margin % is 8.85%, which is near median its own 10-year median of 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.82, compared to a current price of ฿5.50 — trading 49.2% below its estimated fair value. The current EBITDA Margin % is 8.85%, which is near median its 10-year median of 9.47 and 13.6% below the Healthcare Providers & Services industry median of 10.24. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current EBITDA Margin % is 8.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.50 is trading 49.2% below its estimated GF Value™ of ฿10.82.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
EBITDA Margin %: 8.85% (near median its 10-year median of 9.47)
GF Value™: ฿10.82 vs. price of ฿5.50 (49.2% below fair value)
Industry Position: 13.6% below the Healthcare Providers & Services median (#352 of 665)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score
Get the complete analysis for BKK:HL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
